How were Urovant Sciences' earnings last quarter?

Urovant Sciences Ltd. (NASDAQ:UROV) announced its quarterly earnings results on Thursday, February, 11th. The company reported ($1.46) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.59) by $0.13.

What other stocks do shareholders of Urovant Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Urovant Sciences investors own include Fulcrum Therapeutics (FULC) , Aldeyra Therapeutics (ALDX) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , AVEO Pharmaceuticals (AVEO) , Idera Pharmaceuticals (IDRA) , OPKO Health (OPK) , Provention Bio (PRVB) , SCYNEXIS (SCYX) and Xeris Biopharma (XERS) .

When did Urovant Sciences IPO?

Urovant Sciences (UROV) raised $150 million in an initial public offering on Thursday, September 27th 2018. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO.

NASDAQ:UROV

Urovant Sciences (UROV) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free UROV Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $16.24
▼
$16.24
50-Day Range: $16.19
▼
$16.24
52-Week Range: $7.15
▼
$16.26

Volume: N/A
Average Volume: 114,469 shs
Market Capitalization: $531.75 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Urovant Sciences alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Urovant Sciences Stock (NASDAQ:UROV)

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

Click for my No. 1 investment, all free of charge, click here.

UROV Stock News Headlines

March 26, 2024 | finance.yahoo.com

A2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directors

December 6, 2023 | finance.yahoo.com

Petauri™ Elects William Fleming and James Robinson to Its Board of Directors

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

October 4, 2023 | finance.yahoo.com

PM360 Announces 2023 Trailblazer Award Winners

September 11, 2023 | finance.yahoo.com

Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors

July 31, 2023 | finance.yahoo.com

CNVCF - BioHarvest Sciences Inc.

July 25, 2023 | businesswire.com

UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors

July 20, 2023 | benzinga.com

Benign Prostatic Hyperplasia Therapeutics Market Size Predictions suggest a rise of 5.1% CAGR, to reach value of USD 12.9 Billion by 2032

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

June 24, 2023 | npr.org

KPCW Cool Science Radio

June 9, 2023 | uk.finance.yahoo.com

Overactive Bladder Treatment Global Market Report 2023

May 22, 2023 | finanznachrichten.de

Pierre Fabre announces start of EU marketing authorization application procedure for Vibegron in overactive bladder

May 3, 2023 | bizjournals.com

Three Japanese pharma subsidiaries to lay off 223 in Marlborough

March 28, 2023 | finance.yahoo.com

Overactive Bladder Market to Grow Rapidly at a Considerable CAGR During the Forecast Period (2023–2032) | DelveInsight

February 19, 2023 | marketwatch.com

Drugs for Enuresis Market 2023: Growth by 2029 Top Players with Opportunities

January 19, 2023 | technews.tmcnet.com

Urovant Sciences® Announces Collaboration with Holly Robinson Peete to Help Raise Awareness for Overactive Bladder and Treatment Options

January 16, 2023 | marketwatch.com

Drugs for Enuresis Market Share From 2023 To 2029 And Unlimited Opportunities for New Companies and Latest Developments

December 21, 2022 | msn.com

How To Deal With An Overactive Bladder If You're Traveling Long Distance Over The Holidays

December 20, 2022 | seekingalpha.com

Roivant Sciences: A Solid Year Of Progress And Good Prospects For 2023

October 27, 2022 | finance.yahoo.com

Urovant Sciences Announces Publication of Pharmacokinetic Data on GEMTESA® (Vibegron 75mg) Administered as an Intact or Crushed Tablet

October 4, 2022 | seekingalpha.com

Myovant: Sumitomo Bid Is A Head Scratcher, Where Is The Value?

September 30, 2022 | financialpost.com

'I lose money every time I leave the house': Inflation complicates back-to-office push

September 26, 2022 | investopedia.com

Social Science: What It Is and the 5 Major Branches

September 13, 2022 | usnews.com

Best Global Universities for Computer Science

September 10, 2022 | npr.org

Science Friday

September 8, 2022 | cnbc.com

Health and Science

September 7, 2022 | finanznachrichten.de

Urovant Sciences, Inc.: Urovant Sciences Named 17th on the List of Fortune Best Workplaces in BioPharma (2022)

See More Headlines

Receive UROV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Urovant Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/11/2021
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:UROV
CUSIP: N/A
CIK: 1740547
Web: www.urovant.com
Phone: 44-0-20-7400-3347
Fax: N/A
Employees: 70
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($4.71)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-146,740,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -162.90%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.91
Quick Ratio: 2.91

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.90) per share
Price / Book: -8.55

Miscellaneous

Outstanding Shares: 32,743,000
Free Float: N/A
Market Cap: $531.75 million
Optionable: Not Optionable
Beta: 2.36

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. James A. Robinson Jr. (Age 50)
Pres, CEO & Director
Comp: $1.07M
Mr. Ajay Bansal (Age 59)
CFO & Sr. VP of Bus. Devel.
Comp: $558.34k
Dr. Cornelia Haag-Molkenteller M.D. (Age 62)
Ph.D., Chief Medical Officer of USI
Comp: $629.79k
Ms. Christine G. Ocampo (Age 49)
Chief Accounting Officer & Sr. VP
Ryan Kubota
Exec. Director of Investor Relations
Mr. Bryan E. Smith (Age 42)
Gen. Counsel
Dr. David Hovland
Sr. VP of Global Regulatory Affairs
Mr. Kenton Stewart
Sr. VP of Market Access

Key Competitors

View All Competitors

UROV Stock Analysis - Frequently Asked Questions

How were Urovant Sciences' earnings last quarter?: Urovant Sciences Ltd. (NASDAQ:UROV) announced its quarterly earnings results on Thursday, February, 11th. The company reported ($1.46) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.59) by $0.13.
What other stocks do shareholders of Urovant Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Urovant Sciences investors own include Fulcrum Therapeutics (FULC), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), AVEO Pharmaceuticals (AVEO), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Provention Bio (PRVB), SCYNEXIS (SCYX) and Xeris Biopharma (XERS).
When did Urovant Sciences IPO?: Urovant Sciences (UROV) raised $150 million in an initial public offering on Thursday, September 27th 2018. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO.

This page (NASDAQ:UROV) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Urovant Sciences (UROV) Stock Price, News & Analysis

About Urovant Sciences Stock (NASDAQ:UROV)

UROV Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

UROV Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info